PD-1 Data Promise More Shake-ups In Melanoma Standard of Care
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.